Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer

Anticancer Res. 2009 Jul;29(7):2739-45.


Background: In the present study, the effect of immunochemotherapy with lentinan compared with that of chemotherapy alone was evaluated in patients with advanced gastric cancer through individual patient data (IPD) meta-analysis.

Materials and methods: Based on a computerized and manual search, all eligible centrally randomized controlled trials (RCT) which compared chemotherapy regimens with or without lentinan administration for advanced gastric cancer patients were included.

Results: In total, 650 IPD from 5 trials were available. Lentinan significantly prolonged the overall survival (stratified log-rank p=0.011). The overall hazard ratio (HR) was 0.80 (95% confidence interval=0.68-0.95) and there was no heterogeneity between trials. Additionally, lentinan was possibly more effective in patients with lymph-node metastasis than in non-node metastasis patients (P for interaction=0.077).

Conclusion: The addition of lentinan to standard chemotherapy offers a significant advantage over chemotherapy alone in terms of survival for patients with advanced gastric cancer.

Publication types

  • Meta-Analysis

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Lentinan / therapeutic use*
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Stomach Neoplasms / drug therapy*


  • Antineoplastic Agents
  • Lentinan